Adaptive Trial Designs
Reducing costs and improving efficiency in clinical development
Adaptive trial designs offer significant benefits for biopharmaceutical companies looking to reduce costs and streamline the drug development process, increasing efficiency and success rates for their clinical programs. Adaptive trials use accumulating trial data with a prospective design to determine how to change aspects of a study, while maintaining study validity and integrity.
The efficacy of the adaptive design and strength of conclusions are understood through trial simulation techniques. These simulations allow clients to understand completely the adaptive design—building designs as though they were looking at the data and making decisions.
The PPD™ clinical research business of Thermo Fisher Scientific’s experience in planning and executing adaptive trials can deliver significant advantages to our clients through:
- In-depth global resources, including exceptional biostatistical, medical and regulatory expertise
- Close consultation with clients, beginning in early development, to explore the advantages and requirements of an adaptive design approach and define an appropriate strategy
- Diverse therapeutic experience in adaptive trial designs, including oncology, general medicine, nervous system disorders, metabolic disorders, infectious diseases and autoimmune disorders
- A strong collaboration with Berry Consultants, a leading statistical consulting group specializing in adaptive clinical trial design with a long history of building adaptive Bayesian designs
Want to learn more?
PPD to open new clinical research unit in Las Vegas
Complete expertise and resources to plan and execute adaptive trial designs
The investment in early, in-depth planning utilizing adaptive trial designs can lead to significant benefits, including:
- Faster “go/no-go” decisions, saving time and money by more efficiently allocating subjects in the trial to the most effective doses, creating a better understanding of the efficacy and safety profile
- Better early development decisions on the dose and frequency, increasing the likelihood of Phase III success
- Critical information to stop trials for ineffective or unsafe drugs more quickly, increasing safety and improving patient experience